The OMNI Surgical System appears to be not only clinically effective but also budgetary efficient from the perspective of US payers, according to a new study. Its adoption fills an unmet need in the treatment paradigm for glaucoma patients, offering a minimally invasive alternative between topical intraocular pressure medicines and more invasive filtration procedures.
A recent study evaluated the adoption of the OMNI Surgical System as a minimally invasive treatment option for primary open-angle glaucoma patients. The study aimed to assess the budget impact of incorporating the OMNI system, with or without cataract surgery, in a hypothetical US health plan covering 1 million Medicare beneficiaries over a 2-year period.
The research, which included primary investigations with key opinion leaders and payers, employed a budget impact analysis to estimate costs before and after the implementation of the system. Data for the model were obtained from published sources and primary research, ensuring comprehensive analysis and accurate results.
Comparing the total annual direct costs of the OMNI Surgical System with other treatment options, such as topical intraocular pressure medicines, other minimally invasive surgical procedures, and selective laser trabeculoplasty, the study found that increased adoption of OMNI resulted in budget neutrality over the 2-year timeframe. The total costs decreased by $35,362, indicating a cost-saving benefit.
Furthermore, when used without cataract surgery, the OMNI system incurred no additional costs per member per month, demonstrating its potential to be a financially efficient treatment option. When used in conjunction with cataract surgery, the system yielded cost savings of -$0.01 per member per month.
To validate the robustness of the model, a one-way sensitivity analysis was conducted to assess parameter uncertainty. The results affirmed the reliability of the findings and highlighted the variability of surgical center fees as a significant driver of costs.
Reference
Mader G, Ghinelli F, Torelli F, et al. The budget impact of introducing the OMNI® surgical system to a United States health plan for managing mild-to-moderate primary open-angle glaucoma. Expert Rev Pharmacoecon Outcomes Res. 2023;doi: 10.1080/14737167.2023.2217357. Epub ahead of print. PMID: 37224422.
Related Content
